AD/PD 2021 | Donanemab in early-stage AD: a highlight from AD/PD

Sangram Sisodia, PhD, University of Chicago, Chicago, IL, discusses the data reported at the AD/PD™ 2021 conference from the Phase II TRAILBLAZER-ALZ study (NCT03367403) of donanemab, a humanized IgG1 monoclonal antibody, in patients with early symptomatic Alzheimer’s disease (AD). He highlights the use of the novel Integrated Alzheimer’s Disease Rating Scale (iADRS) as the trial’s primary outcome measure and suggests that the strategy used to enrol patients with early-stage AD based on tau PET imaging should be replicated in future studies. This interview took place during the AD/PD™ 2021 conference.